Correction to: Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients

Basson, Yael Pri-Paz; Tayer-Shifman, Oshrat E; Naser, Rawand; Matalon, Shay; Kimhi, Oded; Gepstein, Raz; Halperin, Tami; Ziv‐Baran, Tomer; Ziv, Amit; Parikh, Roma; Kivity, Shaye; Levy, Yair

doi:10.1007/s10067-022-06412-8

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of anti-COVID-19 vaccination are reported in small patients' series [ [31] , [32] , [33] , [34] , [35] , [36] ], showing a generally good tolerability to different anti-COVID-19 vaccines, mostly mRNA types [ [19] , [20] , [21] , 35 , 37 ]. The percentage of impaired seroconversion largely varied among different patients’ series [ 19 , 31 , 34 , 37 , 38 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

Ferri,

Raimondo,

Giuggioli

et al. 2023

Journal of Translational Autoimmunity

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

Ferri,

Raimondo,

Giuggioli

et al. 2023

Journal of Translational Autoimmunity

View full text Add to dashboard Cite

Steroid treatment suppresses the CD4+ T-cell response to the third dose of mRNA COVID-19 vaccine in systemic autoimmune rheumatic disease patients

Maliah

Parikh

Tayer-Shifman

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Prolonged steroid treatment has a suppressive effect on the immune system, however, its effect on the cellular response to mRNA vaccine is unknown. Here we assessed the impact of prolonged steroid treatment on the T-cell and humoral response to the SARS-CoV-2 spike (S) peptide following the third dose of the BNT162b2 vaccine in systemic autoimmune rheumatic disease patients. We found that CD4 T-cell response to the S peptide in patients on high-dose long-term steroid treatment showed significantly less S-peptide specific response, compare to low-dose or untreated patients. Remarkably, these results were not reflected in their humoral response, since almost all patients in the cohort had sufficient antibody levels. Moreover, S-peptide activation failed to induce significant mRNA levels of IFNγ and TNFα in patients receiving high-dose steroids. RNA-sequencing datasets analysis implies that steroid treatments' inhibitory effect of nuclear factor kappa-B signaling may interfere with the activation of S-specific CD4 T-cells. This reveals that high-dose steroid treatment inhibits T-cell response to the mRNA vaccine, despite having sufficient antibody levels. Since T-cell immunity is a crucial factor in the immune response to viruses, our findings highlight the need for enhancing the efficiency of vaccines in immune-suppressive patients, by modulation of the T-cell response.

show abstract

Correction to: Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients

Cited by 2 publications

References 0 publications

Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

Steroid treatment suppresses the CD4+ T-cell response to the third dose of mRNA COVID-19 vaccine in systemic autoimmune rheumatic disease patients

Contact Info

Product

Resources

About